Drug Delivery Business

Sequel Med Tech makes first CGM integration with Abbott for automated insulin pump

By

Abbott FreeStyle Libre 3 Plus Sequel Med Tech Twiist
The twiist system (left) and FreeStyle Libre 3 system (right). [Images courtesy of Sequel Med Tech and Abbott]
Sequel Med Tech announced today that it integrated its twiist automated insulin delivery (AID) with the Abbott FreeStyle Libre 3 Plus sensor.

This marks the first continuous glucose monitor (CGM) integration for twiist. Manchester, New Hampshire-based Sequel expects to launch the combination in the second quarter of 2025.

Sequel won FDA clearance for the twiist system exactly one year ago. (At the American Diabetes Association Scientific Sessions in June, CEO Dr. Alan Lotvin explained the unique advantages of the new system.)

“We are thrilled to announce our collaboration with Abbott, integrating its world-leading FreeStyle Libre technology as our first CGM partner, marking a significant milestone as we bring our innovative AID system to market,” said Lotvin. “This collaboration highlights our commitment to making advanced diabetes management more accessible and flexible for people living with diabetes. Abbott’s FreeStyle Libre technology, known for its user-friendly design and broad accessibility, complements our innovative system.”

twiist, combined with the twiist Loop algorithm, directly measures the volume of insulin delivered with every microdose. It offers the capability and flexibility to address each patient’s individual dosing needs. Sequel’s system utilizes sound waves that measure each pulse of insulin. This enables precision and helps understand exactly how much insulin the patient receives in a dose.

twiist has iiSure technology, which includes four checkpoints to provide accurate delivery and alert users to blockages quickly. Cleared for ages six and up with type 1 diabetes, the system offers a personalized way to manage the condition.

Sequel said it remains dedicated to providing a range of CGM options with its system down the line in addition to Libre 3 Plus.

IN CASE YOU MISSED IT

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.